Basel III May See Funds Deal In More OTCs

© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Basel III May See Funds Deal In More OTCs

Basel III proposals to increase capital charges for counterparty credit risk could give rise to unregulated entities such as hedge funds becoming market makers in the over-the-counter derivatives market, according to a report by Standard & Poor’s.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • 4 capital markets databases
  • Daily newsletters across markets and asset classes
  • 2 weekly podcasts
Gift this article